{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:07:02Z","timestamp":1791994022547,"version":"4.4.0"},"reference-count":228,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,28]],"date-time":"2019-07-28T00:00:00Z","timestamp":1564272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7171012"],"award-info":[{"award-number":["7171012"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC0904900"],"award-info":[{"award-number":["2016YFC0904900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX09304028"],"award-info":[{"award-number":["2017ZX09304028"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573504"],"award-info":[{"award-number":["81573504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.pharmthera.2019.107393","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T11:04:45Z","timestamp":1564139085000},"page":"107393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic"],"prefix":"10.1016","volume":"203","author":[{"given":"Qian","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.107393_bb0005","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","volume":"338","author":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","year":"1998","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0010","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0015","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/j.bmcl.2004.03.043","article-title":"PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues","volume":"14","author":"Abbott","year":"2004","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1074248414546324","article-title":"Hydroxychloroquine's efficacy as an antiplatelet agent study in healthy volunteers: A proof of concept study","volume":"20","author":"Achuthan","year":"2015","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0025","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/and.12387","article-title":"Effect of sildenafil on platelet function and platelet cGMP of patients with erectile dysfunction","volume":"47","author":"Akand","year":"2015","journal-title":"Andrologia"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism","volume":"8","author":"Andre","year":"2002","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1358\/dnp.2007.20.5.1120215","article-title":"The 14-3-3zeta-GPIb-IX-V complex as an antiplatelet target","volume":"20","author":"Andrews","year":"2007","journal-title":"Drug News & Perspectives"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0045","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0306-3623(96)00050-X","article-title":"Interplay between milrinone and adenosine in the inhibition of human platelet response","volume":"27","author":"Anfossi","year":"1996","journal-title":"General Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"Jama"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2337\/db16-1098","article-title":"Platelet hyperreactivity in diabetes: Focus on GPVI signaling-are useful drugs already available?","volume":"66","author":"Arthur","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0060","doi-asserted-by":"crossref","first-page":"E70","DOI":"10.1177\/1076029610384114","article-title":"An anti-von willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis","volume":"17","author":"Arzamendi","year":"2011","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/09537100600565551","article-title":"Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans","volume":"17","author":"Asai","year":"2006","journal-title":"Platelets"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0070","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0075","doi-asserted-by":"crossref","first-page":"763","DOI":"10.6061\/clinics\/2014(11)10","article-title":"The effects of vardenafil and pentoxifylline administration in an animal model of ischemic colitis","volume":"69","author":"Aziret","year":"2014","journal-title":"Clinics (S\u00e3o Paulo, Brazil)"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0080","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1021\/jm400820m","article-title":"Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. Separation of the antithrombotic effect and bleeding for candidate drug AZD1283","volume":"56","author":"Bach","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0085","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s12272-012-1000-3","article-title":"Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an anti-vWF aptamer, against thrombotic risk","volume":"35","author":"Bae","year":"2012","journal-title":"Archives of Pharmacal Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/1570163811209020119","article-title":"New oral anticoagulants for venous thromboembolism: Focus on factor Xa and thrombin inhibitors","volume":"9","author":"Becattini","year":"2012","journal-title":"Current Drug Discovery Technologies"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0095","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.phrs.2016.04.002","article-title":"MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease","volume":"107","author":"Belleville-Rolland","year":"2016","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0100","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4155\/fmc-2017-0001","article-title":"The progress in the research of antiplatelet agents (1995-2017)","volume":"9","author":"Benimana","year":"2017","journal-title":"Future Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0105","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ahj.2009.10.010","volume":"158","author":"Berger","year":"2009","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/315511a0","article-title":"Synthesis and structure of the platelet aggregation factor thromboxane A2","volume":"315","author":"Bhagwat","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0115","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0120","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0125","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.thromres.2011.02.007","article-title":"Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-beta inhibitor in mice","volume":"127","author":"Bird","year":"2011","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2008-08-169243","article-title":"Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist","volume":"114","author":"Blue","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0135","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/jm500588w","article-title":"N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methyl piperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist","volume":"57","author":"Boldron","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0140","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0145","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2014.09.037","article-title":"Coronary stent thrombosis with vorapaxar versus placebo: Results from the TRA 2 degrees P-TIMI 50 trial","volume":"64","author":"Bonaca","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0150","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: Results from TRA2{degrees}P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0155","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","article-title":"Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial","volume":"377","author":"Bousser","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0160","first-page":"V63","article-title":"The German-Austrian aspirin trial: A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction on behalf of the German-Austrian study group","volume":"62","author":"Breddin","year":"1980","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0165","first-page":"325","article-title":"Secondary prevention of myocardial infarction: A comparison of acetylsalicylic acid, placebo and phenprocoumon","volume":"9","author":"Breddin","year":"1980","journal-title":"Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0049-3848(97)00221-1","article-title":"Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro","volume":"88","author":"Buerke","year":"1997","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0175","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"Cannon","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2019.107393_bb0180","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/jth.12952","article-title":"P2Y12 receptors: Structure and function","volume":"13","author":"Cattaneo","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0185","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1074\/jbc.M109714200","article-title":"The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion","volume":"277","author":"Chen","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0190","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/1570180812666150730221941","article-title":"Potent and orally bioavailable antiplatelet agent, PLD-301, with the potential of overcoming clopidogrel resistance","volume":"13","author":"Chen","year":"2016","journal-title":"Letters in Drug Design & Discovery"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0195","first-page":"309","article-title":"NF-kappaB signaling pathway as target for antiplatelet activity","volume":"30","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0200","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jjco\/hys087","article-title":"Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis","volume":"42","author":"Chen","year":"2012","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0205","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jcph.64","article-title":"Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: A meta-analysis","volume":"53","author":"Chen","year":"2013","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0210","first-page":"182","article-title":"Cilostazol","volume":"1","author":"Cheng","year":"1999","journal-title":"Heart Disease"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.anai.2011.08.003","article-title":"Successful use of prasugrel, an alternative antiplatelet agent, in a patient with clopidogrel allergy","volume":"107","author":"Chopra","year":"2011","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0220","first-page":"38","article-title":"Plasma serotonin and platelet aggregation during ischemia-reperfusion in dogs: Effect of dipyridamole and coenzyme Q10","volume":"26","author":"Choudhury","year":"1996","journal-title":"Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0225","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11239-015-1227-1","article-title":"Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction","volume":"41","author":"Cohen","year":"2016","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1042\/BST20150282","article-title":"Proteinase-activated receptors (PARs) as targets for antiplatelet therapy","volume":"44","author":"Cunningham","year":"2016","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1681.2011.05616.x","article-title":"Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans","volume":"39","author":"Cushing","year":"2012","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0240","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/14656566.2017.1421634","article-title":"Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy","volume":"19","author":"Danielak","year":"2018","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0245","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-29423-5_11","article-title":"Thromboxane receptors antagonists and\/or synthase inhibitors","author":"Davi","year":"2012","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0250","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.CIR.98.7.678","article-title":"Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial","volume":"98","author":"Dawson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0255","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/0003319710362977","article-title":"Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: A pilot study","volume":"61","author":"De Bon","year":"2010","journal-title":"Angiology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138945013804806488","article-title":"Stroke prevention: From available antiplatelet drugs to novel molecular targets","volume":"14","author":"Di Minno","year":"2013","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0265","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(08)70198-4","volume":"7","author":"Diener","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0270","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1517\/14656566.2.9.1507","article-title":"ReoPro rules: Results from the 'Do tirofiban and reopro give similar efficacy Trial' (TARGET)","volume":"2","author":"Doggrell","year":"2001","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF03257158","article-title":"Thromboxane A2 inhibition: Therapeutic potential in bronchial asthma","volume":"1","author":"Dogne","year":"2002","journal-title":"American Journal of Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0280","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.12806","article-title":"Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin","volume":"98","author":"Dombi","year":"2017","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0285","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/j.1476-5381.2011.01668.x","article-title":"Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist","volume":"165","author":"Dumas","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0290","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.tips.2012.07.004","article-title":"Platelet GPVI: A target for antithrombotic therapy?!","volume":"33","author":"Dutting","year":"2012","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0295","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0002-9343(83)90528-4","article-title":"British studies of aspirin and myocardial infarction","volume":"74","author":"Elwood","year":"1983","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0300","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.2147\/DDDT.S77221","article-title":"Role of sodium tungstate as a potential antiplatelet agent","volume":"9","author":"Fernandez-Ruiz","year":"2015","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0305","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1089\/ars.2011.4324","article-title":"Platelet function in health and disease: From molecular mechanisms, redox considerations to novel therapeutic opportunities","volume":"17","author":"Ferroni","year":"2012","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0310","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/j.1538-7836.2010.04020.x","article-title":"Thromboxane antagonism with terutroban in peripheral arterial disease: The TAIPAD study","volume":"8","author":"Fiessinger","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.20140391","article-title":"Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators","volume":"212","author":"Flierl","year":"2015","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0320","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1111\/j.1538-7836.2011.04446.x","article-title":"The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin","volume":"9","author":"Fontana","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0325","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/09537104.2012.704648","article-title":"Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers","volume":"24","author":"Fox","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0330","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vph.2014.05.008","article-title":"Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: New antiplatelet agents","volume":"62","author":"Fuentes","year":"2014","journal-title":"Vascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0335","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2014.04.027","article-title":"Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk","volume":"134","author":"Fuentes","year":"2014","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0340","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.blre.2016.03.002","article-title":"NF-kappaB signaling pathway as target for antiplatelet activity","volume":"30","author":"Fuentes","year":"2016","journal-title":"Blood Reviews"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0345","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molmed.2004.02.008","article-title":"Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation","volume":"10","author":"Furie","year":"2004","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0350","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.pharmtox.46.120604.141207","article-title":"Regulation of platelet functions by P2 receptors","volume":"46","author":"Gachet","year":"2006","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0355","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bcmd.2005.12.024","article-title":"The platelet P2 receptors in arterial thrombosis","volume":"36","author":"Gachet","year":"2006","journal-title":"Blood Cells, Molecules & Diseases"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0360","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000338812","article-title":"Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: A meta-analysis of 5,821 patients","volume":"122","author":"Geng","year":"2012","journal-title":"Cardiology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0365","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The canadian American ticlopidine study (CATS) in thromboembolic stroke","volume":"1","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0370","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0375","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/2229-516X.112234","article-title":"Ticagrelor: The first approved reversible oral antiplatelet agent","volume":"3","author":"Goel","year":"2013","journal-title":"International Journal of Applied & Basic Medical Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0380","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","article-title":"Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease","volume":"31","author":"Goto","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0385","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5551\/jat.3038","article-title":"Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome","volume":"17","author":"Goto","year":"2010","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0390","first-page":"80","article-title":"Do low risk patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel need abciximab infusion? Results of ISAR-REACT study","volume":"44","author":"Gratsianskii","year":"2004","journal-title":"Kardiologiia"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0395","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: Phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0400","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The respond study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0405","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0410","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0415","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000365840","article-title":"Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: Subgroup analysis from the effect of Cilostazol in acute lacunar infarction based on pulsatility index of transcranial doppler (ECLIPse) study","volume":"38","author":"Han","year":"2014","journal-title":"Cerebrovascular Diseases"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0420","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0002-9149(99)80345-2","article-title":"Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb\/IIIa inhibitor during percutaneous coronary intervention","volume":"76","author":"Harrington","year":"1995","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0425","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0430","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine aspirin stroke study group","volume":"321","author":"Hass","year":"1989","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0435","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/2048872614527838","article-title":"Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: Results from the TRACER trial","volume":"3","author":"Held","year":"2014","journal-title":"European Heart Journal Acute Cardiovascular Care"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0440","series-title":"Antithrombotic and thrombolytic therapy: American college of chest physicians evidence-based clinical practice guidelines","first-page":"110s","volume":"133","author":"Hirsh","year":"2008"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0445","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI79070","article-title":"Inflammation drives thrombosis after salmonella infection via CLEC-2 on platelets","volume":"125","author":"Hitchcock","year":"2015","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0450","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0455","first-page":"59","article-title":"Tirofiban or abciximab and sirolimus-eluting or bare metal uncoated stents in primary percutaneous coronary intervention for acute myocardial infarction: Results of multistrategy trial","volume":"48","author":"Iavelov","year":"2008","journal-title":"Kardiologiia"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0460","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","volume":"338","author":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","year":"1998","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0465","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1527-3466.2004.tb00132.x","article-title":"Ramatroban (BAY u 3405): A novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor","volume":"22","author":"Ishizuka","year":"2004","journal-title":"Cardiovascular Drug Reviews"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0470","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0898-6568(96)00112-X","article-title":"Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021","volume":"8","author":"Ito","year":"1996","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0475","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.jacc.2015.03.573","article-title":"Differential inhibition of human atherosclerotic plaque-induced platelet activation by dimeric GPVI-fc and anti-GPVI antibodies: Functional and imaging studies","volume":"65","author":"Jamasbi","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0480","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial","volume":"157","author":"James","year":"2009","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0485","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.006007","article-title":"Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans","volume":"2","author":"Japp","year":"2013","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0490","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/ijs.12384","article-title":"The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial","volume":"10","author":"Jeng","year":"2015","journal-title":"International Journal of Stroke"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0495","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clinthera.2015.01.010","article-title":"Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers","volume":"37","author":"Jeon","year":"2015","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0500","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.bmcl.2014.01.066","volume":"24","author":"Jeon","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0505","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.drudis.2014.06.005","article-title":"New advances in treating thrombotic diseases: GPVI as a platelet drug target","volume":"19","author":"Jiang","year":"2014","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0510","article-title":"Inhibition of glycoprotein VI clustering by collagen as a mechanism of inhibiting collagen-induced platelet responses: The example of losartan","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0515","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.104.073718","volume":"312","author":"Jin","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0520","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/09537100701268741","article-title":"Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589","volume":"18","author":"Johnson","year":"2007","journal-title":"Platelets"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0525","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/jcph.1296","article-title":"Clinical pharmacology of the reversible and potent P2Y12 receptor antagonist ACT-246475 after single subcutaneous administration in healthy male subjects","volume":"59","author":"Juif","year":"2019","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0530","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/0976-500X.107698","article-title":"Ticagrelor: An emerging oral antiplatelet agent","volume":"4","author":"Juneja","year":"2013","journal-title":"Journal of Pharmacology and Pharmacotherapeutics"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0535","doi-asserted-by":"crossref","first-page":"30000","DOI":"10.1074\/jbc.M112.359125","article-title":"Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood","volume":"287","author":"Jung","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0540","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0049-3848(00)00415-1","article-title":"Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol","volume":"101","author":"Kariyazono","year":"2001","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0545","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0550","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0049-3848(01)00351-6","article-title":"Effects of the antiplatelet agent TA-993 and its metabolite MB3 on the hemorheological properties of rat and human erythrocytes","volume":"104","author":"Katoh","year":"2001","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0555","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.2174\/1389557518666180424120726","article-title":"Advances in the development of novel factor xa inhibitors: A patent review","volume":"18","author":"Khadse","year":"2018","journal-title":"Mini Reviews in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0560","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0021-9150(98)00203-2","article-title":"Milrinone, a phosphodiesterase inhibitor, suppresses intimal thickening after photochemically induced endothelial injury in the mouse femoral artery","volume":"142","author":"Kondo","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0565","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-012-1217-6","article-title":"Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease","volume":"68","author":"Kosoglou","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0570","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00228-011-1120-6","article-title":"Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects","volume":"68","author":"Kosoglou","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0575","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00210-010-0505-x","article-title":"NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities","volume":"381","author":"Kuo","year":"2010","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0580","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.2174\/0929867323666160907112038","article-title":"Regulation of platelet function by acetylation\/deacetylation mechanisms","volume":"23","author":"Latorre","year":"2016","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0585","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/j.1538-7836.2003.00495.x","article-title":"Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived fab fragments","volume":"1","author":"Lecut","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0590","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12272-011-0421-8","article-title":"Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent","volume":"34","author":"Lee","year":"2011","journal-title":"Archives of Pharmacal Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0595","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH13-06-0490","article-title":"Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis","volume":"111","author":"Lei","year":"2014","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0600","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/2048872616661692","article-title":"Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The champion experience","volume":"7","author":"Leonardi","year":"2018","journal-title":"European Heart Journal Acute Cardiovascular Care"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0605","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2010.04.008","volume":"160","author":"Leonardi","year":"2010","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0610","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/eurheartj\/eht104","article-title":"Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial","volume":"34","author":"Leonardi","year":"2013","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0615","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/ATVBAHA.107.140590","article-title":"The fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats","volume":"27","author":"Li","year":"2007","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0620","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","article-title":"RUC-4: A novel alphaIIbbeta3 antagonist for prehospital therapy of myocardial infarction","volume":"34","author":"Li","year":"2014","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0625","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(98)00181-2","article-title":"Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy quinol inone (CCT-62)","volume":"349","author":"Liao","year":"1998","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0630","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5152\/iao.2016.2682","article-title":"Effect of a 4-week treatment with Cilostazol in patients with chronic tinnitus: A randomized, prospective, placebo-controlled, double-blind, pilot study","volume":"12","author":"Lim","year":"2016","journal-title":"Journal International Advance Otolaryngol"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0635","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005344-200408000-00017","article-title":"Cilostazol and dipyridamole synergistically inhibit human platelet aggregation","volume":"44","author":"Liu","year":"2004","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0640","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40261-013-0145-2","article-title":"Pharmacodynamics and pharmacokinetics of a novel, low-dose, soft-gel capsule of acetylsalicylic acid in comparison with an oral solution after single-dose administration to healthy volunteers: A phase I, two-way crossover study","volume":"34","author":"Loprete","year":"2014","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0645","series-title":"Probe reports from the NIH molecular libraries program","article-title":"Discovery of ML355, a potent and selective inhibitor of human 12-lipoxygenase","author":"Luci","year":"2010"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0650","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1124\/jpet.111.189050","article-title":"A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents","volume":"341","author":"Mangin","year":"2012","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0655","first-page":"1006","article-title":"Targeting 12-lipoxygenase as a potential novel antiplatelet therapy","volume":"38","author":"Mangin","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0660","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","article-title":"The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: A randomized trial","volume":"42","author":"Markus","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0665","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000445509","article-title":"Effect of Cilostazol on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled trial","volume":"42","author":"Matsuda","year":"2016","journal-title":"Cerebrovascular Diseases"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0670","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.thromres.2006.01.023","article-title":"Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization","volume":"119","author":"Matsumoto","year":"2007","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0675","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0306-3623(96)00190-5","article-title":"The mechanism of action of KBT-3022, a new antiplatelet agent","volume":"28","author":"Matsuo","year":"1997","journal-title":"General Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0680","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.prostaglandins.2015.10.001","article-title":"The receptor EP3 to PGE2: A rational target to prevent atherothrombosis without inducing bleeding","volume":"121","author":"Mawhin","year":"2015","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0685","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0690","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1053\/euhj.2000.2474","article-title":"The Clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease","volume":"21","author":"Mehta","year":"2000","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0695","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0700","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1358\/dnp.2004.17.8.863692","article-title":"G13-mediated signaling as a potential target for antiplatelet drugs","volume":"17","author":"Moers","year":"2004","journal-title":"Drug News & Perspectives"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0705","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ccd.22876","volume":"77","author":"Moliterno","year":"2011","journal-title":"Catheterization and Cardiovascular Interventions"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0710","first-page":"32","article-title":"Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals","volume":"42","author":"Momo","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0715","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1055\/s-0037-1613401","article-title":"A new monoclonal antibody, mAb 204-11, that influences the binding of platelet GPVI to fibrous collagen","volume":"89","author":"Moroi","year":"2003","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0720","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2009.06.027","volume":"158","author":"Morrow","year":"2009","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0725","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/eurheartj\/ehi459","article-title":"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: Do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up","volume":"26","author":"Mukherjee","year":"2005","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0730","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12265-012-9422-3","article-title":"von Willebrand factor inhibition improves endothelial function in patients with stable angina","volume":"6","author":"Muller","year":"2013","journal-title":"Journal of Cardiovascular Translational Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0735","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00129784-200303020-00004","article-title":"The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb\/IIIa receptor inhibitor, in patients with stable coronary artery disease","volume":"3","author":"Murphy","year":"2003","journal-title":"American Journal of Cardiovascular Drugs"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0740","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1054\/plef.2002.0365","article-title":"Effect of ozagrel hydrochloride, a thromboxane synthetase inhibitor, on alcoholic beverage-induced bronchoconstriction in asthmatic patients","volume":"66","author":"Myou","year":"2002","journal-title":"Prostaglandins, Leukotrienes, and Essential Fatty Acids"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0745","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000065669","article-title":"Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma","volume":"14","author":"Nakamura","year":"2002","journal-title":"Cerebrovascular Diseases"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0750","first-page":"60","article-title":"Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in human subjects","volume":"42","author":"Nakashima","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0755","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0049-3848(97)00271-5","article-title":"The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects","volume":"88","author":"Naran","year":"1997","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0760","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ehj.2004.07.013","article-title":"Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study","volume":"25","author":"Neri Serneri","year":"2004","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0765","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0049-3848(91)90029-V","article-title":"In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent","volume":"62","author":"Nicholson","year":"1991","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0770","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood-2015-11-636472","article-title":"Protease-activated receptors in hemostasis","volume":"128","author":"Nieman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0775","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2002-12-3882","article-title":"Platelet-collagen interaction: Is GPVI the central receptor?","volume":"102","author":"Nieswandt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0780","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-2005-869524","article-title":"Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity","volume":"31","author":"Niitsu","year":"2005","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0785","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/09537100410001682779","article-title":"Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: Therapeutic effects by cilostazol and potentiation by dipyridamole","volume":"15","author":"Nomura","year":"2004","journal-title":"Platelets"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0790","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","article-title":"Human target validation of phosphoinositide 3-kinase (PI3K)beta: Effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor","volume":"10","author":"Nylander","year":"2012","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0795","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCULATIONAHA.115.017300","article-title":"Efficacy and safety of Cangrelor in women versus men during percutaneous coronary intervention: Insights from the cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial","volume":"133","author":"O'Donoghue","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0800","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1538-7836.2008.02976.x","article-title":"Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI fab fragment in non-human primates without modification of glycoprotein VI expression","volume":"6","author":"Ohlmann","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0805","first-page":"39","article-title":"Protective effect of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on myocardial damage due to coronary occlusion and reperfusion in rabbit","volume":"42","author":"Ohmuro","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0810","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1021\/jm901534d","article-title":"Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI","volume":"53","author":"Ono","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0815","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.0000046487.06811.5E","article-title":"Long-term results after the glycoprotein IIb\/IIIa inhibitor abciximab in unstable angina: One-year survival in the GUSTO IV-ACS (global use of strategies to open occluded coronary arteries IV--acute coronary syndrome) trial","volume":"107","author":"Ottervanger","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0820","article-title":"BF066, a novel dual target antiplatelet agent without significant bleeding","volume":"7","author":"Pan","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0825","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1745-6215-15-151","article-title":"Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): Study protocol for a randomized controlled trial","volume":"15","author":"Park","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0835","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.CIR.88.4.1512","article-title":"MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb\/IIIa antagonist, is active in man","volume":"88","author":"Peerlinck","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0840","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0845","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1055\/s-0038-1649697","article-title":"Antithrombotic activity of bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: A random controlled clinical trial","volume":"70","author":"Pieters","year":"1993","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0850","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10006-012-0387-9","article-title":"Sildenafil effect on prevention of thrombosis after microsurgical anastomosis: Experimental rat model of thrombotic suture","volume":"18","author":"Pingarron-Martin","year":"2014","journal-title":"Oral and Maxillofacial Surgery"},{"issue":"Suppl A","key":"10.1016\/j.pharmthera.2019.107393_bb0855","first-page":"45A","article-title":"Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb\/IIIa receptor inhibition: The EPIC trial results","volume":"6","author":"Popma","year":"1994","journal-title":"Jounal of Invasive Cardiolgy"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0860","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1016\/j.bmc.2010.04.011","article-title":"Characterization of 4-methyl-2-oxo-1,2-dihydroquinolin-6-yl acetate as an effective antiplatelet agent","volume":"18","author":"Priya","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0865","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood.V96.13.4246","article-title":"Fyn and Lyn phosphorylate the fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway","volume":"96","author":"Quek","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0870","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1046\/j.1532-5415.2002.50604.x","article-title":"Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized controlled trials","volume":"50","author":"Regensteiner","year":"2002","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0875","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.338","article-title":"The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat","volume":"5","author":"Rey","year":"2017","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0880","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/j.1875-9114.1991.tb04295.x","article-title":"Ticlopidine: A new antiplatelet agent for cerebrovascular disease","volume":"11","author":"Robert","year":"1991","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0885","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2217\/fca.09.1","article-title":"Prasugrel: Newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention","volume":"5","author":"Robinson","year":"2009","journal-title":"Future Cardiology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0890","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11239-013-0979-8","article-title":"Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: Results of an in vitro pilot investigation","volume":"37","author":"Rollini","year":"2014","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0895","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.thromres.2012.08.309","article-title":"EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin","volume":"130","author":"Sakariassen","year":"2012","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0900","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1182\/blood-2009-07-230268","article-title":"Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: Implications for thrombus formation","volume":"115","author":"Schulz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0905","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/pgmj.2006.047696","article-title":"Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: The subset from the JUMBO study","volume":"82","author":"Serebruany","year":"2006","journal-title":"Postgraduate Medical Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0910","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/jm300038c","article-title":"Overcoming clopidogrel resistance: Discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent","volume":"55","author":"Shan","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0915","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2004-04-1257","article-title":"Integrins: Dynamic scaffolds for adhesion and signaling in platelets","volume":"104","author":"Shattil","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0920","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0925","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jth.12445","article-title":"Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors","volume":"12","author":"Siller-Matula","year":"2014","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0930","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0404.1999.tb00658.x","article-title":"Second European stroke prevention study: Antiplatelet therapy is effective regardless of age. ESPS2 working group","volume":"99","author":"Sivenius","year":"1999","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0935","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0163-7258(91)90054-P","article-title":"Prostaglandin and thromboxane biosynthesis","volume":"49","author":"Smith","year":"1991","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0940","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0898-6568(99)00085-6","article-title":"Increase of [ca(2+)]i and release of arachidonic acid via activation of M2 receptor coupled to Gi and rho proteins in oesophageal muscle","volume":"12","author":"Sohn","year":"2000","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0945","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00228-012-1269-7","article-title":"Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment","volume":"68","author":"Statkevich","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0950","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0955","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00005344-200210000-00011","article-title":"New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation","volume":"40","author":"Sun","year":"2002","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0960","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12883-017-0800-y","article-title":"Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: A case control study","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Neurology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0965","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI32513","article-title":"A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI\/fc receptor gamma-chain complex","volume":"118","author":"Takayama","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0970","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.CIR.98.11.1085","article-title":"Abciximab (ReoPro, chimeric 7E3 fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb\/IIIa and alpha(v)beta3 integrins","volume":"98","author":"Tam","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0975","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0002-9149(00)00695-0","article-title":"Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention","volume":"85","author":"Tanigawa","year":"2000","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0980","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1517\/13543784.8.11.1893","article-title":"Eptifibatide: A potent inhibitor of the platelet receptor integrin, glycoprotein IIb\/IIIa","volume":"8","author":"Tcheng","year":"1999","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0985","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11239-012-0795-6","article-title":"Pharmacodynamic effects of EV-077: Results of an in vitro pilot investigation in healthy volunteers","volume":"34","author":"Tello-Montoliu","year":"2012","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0990","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1161\/01.CIR.102.20.2466","volume":"102","author":"Theroux","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb0995","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.94.5.899","article-title":"Platelet membrane receptor glycoprotein IIb\/IIIa antagonism in unstable angina","volume":"94","author":"Theroux","year":"1996","journal-title":"The Canadian Lamifiban Study Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1000","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","article-title":"Platelet P2Y12 inhibitors reduce systemic inflammation and its Prothrombotic effects in an experimental human model","volume":"35","author":"Thomas","year":"2015","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1005","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/cvr\/cvt276","article-title":"Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence","volume":"101","author":"Tilly","year":"2014","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2141.2010.08539.x","article-title":"Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: First results from the trinity antiPlatelet responsiveness (TrAP) study","volume":"152","author":"Tobin","year":"2011","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1015","first-page":"75","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease","volume":"5","author":"Toma","year":"2010","journal-title":"The Onset\/Offset study. Maedica (Buchar)"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/bjp.2008.141","article-title":"Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets","volume":"154","author":"Toque","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1025","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.07.010","article-title":"Stroke prevention by cilostazol in patients with atherothrombosis: Meta-analysis of placebo-controlled randomized trials","volume":"18","author":"Uchiyama","year":"2009","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000360811","article-title":"Benefit of cilostazol in patients with high risk of bleeding: Subanalysis of cilostazol stroke prevention study 2","volume":"37","author":"Uchiyama","year":"2014","journal-title":"Cerebrovascular Diseases"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1035","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jcin.2011.05.016","article-title":"Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel","volume":"4","author":"Ueno","year":"2011","journal-title":"JACC. Cardiovascular Interventions"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1040","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/fca.10.67","article-title":"Elinogrel: Pharmacological principles, preclinical and early phase clinical testing","volume":"6","author":"Ueno","year":"2010","journal-title":"Future Cardiology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1045","first-page":"1931","article-title":"PET study of the neuroprotective effect of TRA-418, an antiplatelet agent, in a monkey model of stroke","volume":"46","author":"Umemura","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1050","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (dimeric glycoprotein VI-fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/eurheartj\/ehp376","article-title":"Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: A meta-analysis of randomized trials","volume":"31","author":"Valgimigli","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/ATVBAHA.107.150474","article-title":"Cell adhesion mechanisms in platelets","volume":"28","author":"Varga-Szabo","year":"2008","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1065","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/STROKEAHA.107.496281","article-title":"Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: A meta-analysis","volume":"39","author":"Verro","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1070","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood.V100.13.4462","article-title":"Cdc42\/Rac1-dependent activation of the p21-activated kinase (PAK) regulates human platelet lamellipodia spreading: Implication of the cortical-actin binding protein cortactin","volume":"100","author":"Vidal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10787-011-0099-z","article-title":"Dissolution and pharmacokinetics of a novel micronized aspirin formulation","volume":"20","author":"Voelker","year":"2012","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0049-3848(84)90333-5","article-title":"XC 386: A new antiplatelet agent","volume":"36","author":"Wang","year":"1984","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1090","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.1038\/ncomms15559","article-title":"Leukocyte integrin mac-1 regulates thrombosis via interaction with platelet GPIbalpha","volume":"8","author":"Wang","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/oxfordjournals.eurheartj.a014858","article-title":"More evidence for a beneficial effect of platelet glycoprotein IIb\/IIIa-blockade during coronary interventions. latest results from the EPILOG and CAPTURE trials","volume":"17","author":"van de Werf","year":"1996","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","article-title":"PAR4 (protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo Thrombus formation","volume":"38","author":"Wilson","year":"2018","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1105","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1110","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1021\/jm5006226","article-title":"Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents","volume":"57","author":"Yang","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0006-2952(92)90295-T","article-title":"Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets","volume":"43","author":"Yu","year":"1992","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH09-06-0378","article-title":"A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel a randomised phase I study","volume":"103","author":"Zafar","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1125","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1179\/1743132812Y.0000000022","article-title":"Ozagrel for acute ischemic stroke: A meta-analysis of data from randomized controlled trials","volume":"34","author":"Zhang","year":"2012","journal-title":"Neurological Research"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0773.2001.880404.x","article-title":"Antiplatelet mechanism of 2-chloro-3-(4-hexylphenyl)-amino-1,4-naphthoquinone (NQ304), an antithrombotic agent","volume":"88","author":"Zhang","year":"2001","journal-title":"Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1135","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1161\/01.CIR.100.15.1609","volume":"100","author":"Zhao","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/bloodadvances.2016000711","article-title":"Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura","volume":"1","author":"Zheng","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.pharmthera.2019.107393_bb1145","series-title":"The integrin PSI domain has an endogenous thiol isomerase function and is a novel target for antiplatelet therapy","first-page":"1840","volume":"Vol. 129","author":"Zhu","year":"2017"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:00:36Z","timestamp":1759010436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819301366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":228,"alternative-id":["S0163725819301366"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107393","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107393"}}